Vassiliki Papadimitrakopoulou
Expertise in
13
conditions

Dr. Vassiliki Papadimitrakopoulou

Oncology
Office
1515 Holcombe Blvd Unit 432, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
13
conditions
Office
1515 Holcombe Blvd Unit 432, 
Houston, TX 

Overview

Vassiliki Papadimitrakopoulou is an Oncologist in Houston, Texas. Dr. Papadimitrakopoulou is highly rated in 13 conditions, according to our data. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy.

Her clinical research consists of co-authoring 125 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D

Locations

Office
1515 Holcombe Blvd Unit 432, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: February 09, 2026
Intervention Type: Drug
Study Drugs: Itacitinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer - (IM-BATTLE-2 Program)
A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer - (IM-BATTLE-2 Program)
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Pembrolizumab, Trametinib
Study Phase: Phase 1/Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer
A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: February 28, 2022
Intervention Type: Drug
Study Drugs: EGF816, INC280, Nivolumab
Study Phase: Phase 2
View 9 Less Clinical Trials

125 Total Publications

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Journal: Nature
Published: February 27, 2025
Similar Doctors
Hagop Kantarjian
Expertise in
47
conditions
Dr. Hagop Kantarjian
Oncology
Expertise in
47
conditions
Dr. Hagop Kantarjian
Oncology

Office

1400 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.3 miles away)
713-792-2813
Languages Spoken:
English
See accepted insurances

Hagop Kantarjian is an Oncologist in Houston, Texas. Dr. Kantarjian is highly rated in 47 conditions, according to our data. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Naval Daver
Expertise in
40
conditions
Dr. Naval Daver
Oncology
Expertise in
40
conditions
Dr. Naval Daver
Oncology

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
 (0.3 miles away)
713-794-4392
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naval Daver is an Oncologist in Houston, Texas. Dr. Daver is highly rated in 40 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
28
conditions
Dr. Neeta Somaiah
Oncology
Expertise in
28
conditions
Dr. Neeta Somaiah
Oncology

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (0.1 miles away)
713-792-8850
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Neeta Somaiah is an Oncologist in Houston, Texas. Dr. Somaiah is highly rated in 28 conditions, according to our data. Her top areas of expertise are Liposarcoma, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Gastrointestinal Stromal Tumor, and Hepato-Pancreato-Biliary Surgery.

Frequently Asked Questions about Dr. Vassiliki Papadimitrakopoulou

How do I make an appointment with Dr. Vassiliki Papadimitrakopoulou?

You can book an appointment with Dr. Vassiliki Papadimitrakopoulou by calling their office at 713-792-6110. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vassiliki Papadimitrakopoulou a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vassiliki Papadimitrakopoulou is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vassiliki Papadimitrakopoulou specialize in?

While Dr. Vassiliki Papadimitrakopoulou is a Oncology, they have specific expertise in Lung Cancer, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Vassiliki Papadimitrakopoulou participate in research or clinical trials?

Yes. Dr. Vassiliki Papadimitrakopoulou has published 125 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Vassiliki Papadimitrakopoulou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vassiliki Papadimitrakopoulou accept my insurance?

Dr. Vassiliki Papadimitrakopoulou accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 713-792-6110 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Papadimitrakopoulou's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile